Healthcare Resources Use in Patients with Human Immunodeficiency Virus (HIV). Real-World Evidence From Six Italian Local Health Units
DOI:
https://doi.org/10.7175/fe.v19i1.1353Keywords:
Human Immunodeficiency Virus (HIV), Antiretroviral therapy (ART), Healthcare resource use, Costs, Comorbidities, Real-world evidenceAbstract
AIM: The aim of the study was to evaluate healthcare resource use and related costs for the management of people living with Human Immunodeficiency Virus (PLWHIV) with and without comorbidities, and to compare the burden of comorbidities in PLWHIV to the general population.METHODS: An observational retrospective analysis, based on administrative and laboratory databases from 6 Italian Local Health Units (LHUs) was performed. Individuals receiving either an HIV treatment [Antiretroviral therapy (ART) – ATC code: J05A)], or with an HIV positive laboratory test result between January 1st, 2014 and December 31st, 2014 were included. The date of first ART prescription or positive test of HIV was used as the Index Date (ID). Patients enrolled were followed-up for all time available from the ID (follow-up period) and their clinical characteristics were investigated from one year prior to the ID (characterization period). Comorbidities were measured by using the Charlson Comorbidity Index; findings were compared with those of a sample of the general population with the same age and sex distribution (OsMed 2015). Healthcare resource use and related cost was evaluated during the follow-up period.
RESULTS: 1,214 patients were included, 837 were PLWHIV without any comorbidities and 377 were PLWHIV with at least one comorbidity. Mean prevalence of prescriptions for treatment of comorbidities was higher in the HIV-infected population than in the Italian general population. The annual healthcare cost of managing HIV patients with comorbidities, was significantly higher than that for patients without comorbidities (€ 10,615 vs. € 8,665, p < 0.001).
CONCLUSIONS: Study results showed that 30% of PLWHIV had at least one comorbidity. The cost of managing PLWHIV who have comorbidities was significantly higher than that of managing PLWHIV without comorbidities. Our data confirm that care and treatment services should be adapted to address the specific needs of people living with both HIV and comorbidities.
References
Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis 2015; 15: 810-8; https://doi.org/10.1016/S1473-3099(15)00056-0
Mahy M, Autenrieth CS, Stanecki K, et al. Increasing trends in HIV prevalence among people aged 50 years and older: evidence from estimates and survey data. AIDS 2014; 28: S453-9; https://doi.org/10.1097/QAD.0000000000000479
Van Sighem A, Gras L, Reiss P, et al. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 2010; 24: 1527-35; https://doi.org/10.1097/QAD.0b013e32833a3946
Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26: 335-43; https://doi.org/10.1097/QAD.0b013e32834dcec9
Nakagawa F, May M, Phillips A. Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis 2013; 26: 17-25; https://doi.org/10.1097/QCO.0b013e32835ba6b1
Guaraldi G, Malagoli A, Calcagno A, et al. The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 - 74 years and more than 75 years. BMC Geriatr 2018; 18: 99; https://doi.org/10.1186/s12877-018-0789-0
Foglia E, Maggiolo F, Quirino T, et al. Multiple Pill Regimens, Single Tablet Regimens and Hiv+ Patients Quality of Life: Evidence from the Straq Study. Value Health 2015; 18: A591; https://doi.org/10.1016/j.jval.2015.09.1521
Venturini A, Cenderello G, Di Biagio A, et al. Quality of life in an Italian cohort of people living with HIV in the era of combined antiretroviral therapy (Evidence from I.A.N.U.A. study-investigation on antiretroviral therapy). AIDS Care 2017; 29: 1373-7; https://doi.org/10.1080/09540121.2017.1286286
Mpondo BCT. HIV Infection in the Elderly: Arising Challenges. J Aging Res 2016; 2016: 1-10; https://doi.org/10.1155/2016/2404857
De Socio GV, Ricci E, Maggi P, et al. Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: the HIV and Hypertension Study. J Hypertens 2017; 35: 409-16; https://doi.org/10.1097/HJH.0000000000001150
Bandera A, Gori A, Sabbatini F, et al. Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. PLoS One 2015; 10: e0124252; https://doi.org/10.1371/journal.pone.0124252
Borderi M1, Calza L, Colangeli V, et al. Prevalence of sub-clinical vertebral fractures in HIV-infected patients. New Microbiol 2014; 37: 25-32
Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. AIDS 2010; 24: 2705-15; https://doi.org/10.1097/QAD.0b013e32833f3c14
Guaraldi G, Zona S, Menozzi M, et al. Cost of noninfectious comorbidities in patients with HIV. Clinicoecon Outcomes Res 2013; 5: 481-8; https://doi.org/10.2147/CEOR.S40607
Perrone V, Saragoni S, Buda S, et al. Pharmacoutilization of epoetins in naive patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimiliars. Biol Targets Ther 2016; 10: 157-65; https://doi.org/10.2147/BTT.S114625
Agenzia Italiana del Farmaco (AIFA). Guideline for the classification and conduction of the observational studies on medicines. 2010. Available at https://www.agenziafarmaco.gov.it/ricclin/sites/default/files/files_wysiwyg/files/CIRCULARS/Circular%2031st%20May%202010.pdf (last accessed June 2018)
Centers for Disease Control and Prevention. Atrial Fibrillation Fact Sheet. Centers for Disease Control and Prevention Website. Available at https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_atrial_fibrillation.html (last accessed June 2018)
Agenzia Italiana del Farmaco (AIFA). L’uso dei farmaci in Italia—rapporto OsMed 2015. Available at http://www.agenziafarmaco.gov.it/sites/default/files/Rapporto_OsMed2015.pdf (last accessed June 2018)
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83
Lorenc A, Ananthavarathan P, Lorigan J, et al. The prevalence of comorbidities among people living with HIV in Brent: a diverse London Borough. Lond J Prim Care 2014; 6: 84-90
Rodriguez-Penney AT, Iudicello JE, Riggs PK, et al. Co-Morbidities in Persons Infected with HIV: Increased Burden with Older Age and Negative Effects on Health-Related Quality of Life. AIDS Patient Care STDs 2013; 27: 5-16; https://doi.org/10.1089/apc.2012.0329
AIDS info. Considerations for Antiretroviral Use in Special Patient Populations HIV and the Older Patient. Available at https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/277/hiv-and-the-older-patient (last accessed June 2018)
Goulet JL, Fultz SL, Rimland D, et al. Do Patterns of Comorbidity Vary by HIV Status, Age, and HIV Severity? Clin Infect Dis 2007; 45: 1593-601; https://doi.org/10.1086/523577
Wu P-Y, Chen M-Y, Hsieh S-M, et al. Comorbidities among the HIV-Infected Patients Aged 40 Years or Older in Taiwan. Huang L-M, editor. PLoS ONE 2014; 9: e104945; https://doi.org/10.1371/journal.pone.0104945
Ranzani A, Oreni L, Agrò M, et al. Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older. J Acquir Immune Defic Syndr 2018; 78: 193-201; https://doi.org/10.1097/QAI.0000000000001653
Ssonko M, Stanaway F, Mayanja HK, et al. Polypharmacy among HIV positive older adults on anti-retroviral therapy attending an urban clinic in Uganda. BMC Geriatr 2018; 18: 125; https://doi.org/10.1186/s12877-018-0817-0
Caro-Vega Y, Belaunzarán-Zamudio PF, Crabtree-Ramírez B, et al. Trends in proportion of older HIV-infected people in care in Latin America and the Caribbean: a growing challenge. Epidemiol Infect 2018: 1-4; https://doi.org/10.1017/S0950268818001346
Nachega JB, Hsu AJ, Uthman OA, et al. Antiretroviral therapy adherence and drug–drug interactions in the aging HIV population. AIDS 2012; 26: S39-53; https://doi.org/10.1097/QAD.0b013e32835584ea
Tseng A, Szadkowski L, Walmsley S, et al. Association of Age With Polypharmacy and Risk of Drug Interactions With Antiretroviral Medications in HIV-Positive Patients. Ann Pharmacother 2013; 47: 1429-39; https://doi.org/10.1177/1060028013504075
Capeau J. Premature Aging and Premature Age-Related Comorbidities in HIV-Infected Patients: Facts and Hypotheses. Clin Infect Dis 2011; 53: 1127-9; https://doi.org/10.1093/cid/cir628
Smit M, Cassidy R, Cozzi-Lepri A, et al. Quantifying the future clinical burden of an ageing HIV-positive population in Italy: a mathematical modelling study. Geneva: International AIDS Society, 2016
Girardi E, D’arminio Monforte A, Camoni L, et al. Curare la malattia da HIV: ritorno al paziente? Recenti Prog Med 2016; 107: 525-50
Quiros-Roldan E, Magoni M, Raffetti E, et al. The burden of chronic diseases and cost-of-care in subjects with HIV infection in a Health District of Northern Italy over a 12-year period compared to that of the general population. BMC Public Health 2016; 16: 1146; https://doi.org/10.1186/s12889-016-3804-4
Published
Issue
Section
License
>> DISTRIBUTION / LICENSE <<
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
